22.53
price down icon0.40%   -0.09
after-market Dopo l'orario di chiusura: 22.17 -0.36 -1.60%
loading
Precedente Chiudi:
$22.62
Aprire:
$22.55
Volume 24 ore:
2.08M
Relative Volume:
1.00
Capitalizzazione di mercato:
$3.80B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
125.17
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
+5.33%
1M Prestazione:
+5.68%
6M Prestazione:
+56.13%
1 anno Prestazione:
+52.85%
Intervallo 1D:
Value
$22.05
$22.92
Intervallo di 1 settimana:
Value
$21.07
$23.05
Portata 52W:
Value
$13.40
$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Nome
Acadia Pharmaceuticals Inc
Name
Telefono
858-558-2871
Name
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Name
Dipendente
654
Name
Cinguettio
@acadiapharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
ACAD's Discussions on Twitter

Confronta ACAD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
22.53 3.82B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.25B 4.58B 3.56B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-21 Iniziato Citigroup Buy
2025-05-21 Aggiornamento Deutsche Bank Hold → Buy
2025-02-11 Iniziato Deutsche Bank Hold
2025-01-03 Downgrade Guggenheim Buy → Neutral
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-03-12 Downgrade Mizuho Buy → Neutral
2024-03-12 Reiterato Needham Buy
2024-01-30 Iniziato Robert W. Baird Outperform
2024-01-24 Aggiornamento Needham Hold → Buy
2023-12-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-12-14 Downgrade Deutsche Bank Buy → Hold
2023-12-13 Iniziato Citigroup Buy
2023-12-12 Iniziato Deutsche Bank Buy
2023-11-06 Aggiornamento Mizuho Neutral → Buy
2023-10-17 Iniziato UBS Buy
2023-10-10 Aggiornamento JP Morgan Neutral → Overweight
2023-01-03 Aggiornamento Guggenheim Neutral → Buy
2022-11-04 Downgrade Goldman Neutral → Sell
2022-11-01 Iniziato Loop Capital Hold
2022-08-08 Downgrade Citigroup Buy → Neutral
2022-08-05 Downgrade Citigroup Buy → Neutral
2022-06-21 Downgrade Jefferies Buy → Underperform
2022-06-16 Aggiornamento Jefferies Hold → Buy
2022-03-16 Aggiornamento Canaccord Genuity Hold → Buy
2022-02-09 Aggiornamento H.C. Wainwright Neutral → Buy
2022-01-05 Aggiornamento Citigroup Neutral → Buy
2021-12-21 Downgrade Guggenheim Buy → Neutral
2021-11-01 Aggiornamento Guggenheim Neutral → Buy
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-06-10 Iniziato Berenberg Hold
2021-04-07 Downgrade H.C. Wainwright Buy → Neutral
2021-04-06 Downgrade Canaccord Genuity Buy → Hold
2021-04-06 Downgrade Goldman Buy → Neutral
2021-04-06 Downgrade Jefferies Buy → Hold
2021-04-06 Downgrade Mizuho Buy → Neutral
2021-04-05 Downgrade Raymond James Outperform → Mkt Perform
2021-03-10 Downgrade BofA Securities Buy → Neutral
2021-03-09 Downgrade Citigroup Buy → Neutral
2021-03-09 Downgrade Guggenheim Buy → Neutral
2021-03-09 Reiterato H.C. Wainwright Buy
2021-03-09 Downgrade Raymond James Strong Buy → Outperform
2021-03-09 Downgrade Stifel Buy → Hold
2020-12-16 Iniziato Mizuho Buy
2020-11-16 Aggiornamento Raymond James Outperform → Strong Buy
2020-08-25 Iniziato Raymond James Outperform
2020-08-20 Iniziato Morgan Stanley Overweight
2020-07-07 Aggiornamento Stifel Hold → Buy
2020-04-16 Iniziato Jefferies Buy
2020-03-31 Aggiornamento Goldman Neutral → Buy
2020-03-06 Iniziato Citigroup Buy
2019-12-16 Iniziato Guggenheim Buy
2019-10-24 Iniziato Oppenheimer Perform
2019-10-01 Iniziato RBC Capital Mkts Outperform
2019-09-13 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-09-10 Aggiornamento Canaccord Genuity Hold → Buy
2019-07-23 Reiterato Needham Buy
2018-12-10 Iniziato Canaccord Genuity Hold
2018-09-21 Aggiornamento Piper Jaffray Neutral → Overweight
2018-08-09 Reiterato Stifel Hold
2018-08-07 Iniziato Stifel Hold
2018-08-06 Downgrade Piper Jaffray Overweight → Neutral
2017-10-06 Ripresa Goldman Neutral
Mostra tutto

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

pulisher
10:00 AM

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

10:00 AM
pulisher
08:14 AM

Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekers - newser.com

08:14 AM
pulisher
06:42 AM

Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Sentiment Review & Community Trade Idea Sharing - newser.com

06:42 AM
pulisher
01:50 AM

Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsRisk Management & Daily Growth Stock Tips - newser.com

01:50 AM
pulisher
12:49 PM

Understanding ACADIA Pharmaceuticals Inc.’s price movementJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com

12:49 PM
pulisher
Oct 28, 2025

Acadia Pharmaceuticals (NASDAQ: ACAD) to Join UBS and Jefferies Healthcare Conferences - Stock Titan

Oct 28, 2025
pulisher
Oct 28, 2025

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire

Oct 28, 2025
pulisher
Oct 28, 2025

Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Is ACADIA Pharmaceuticals Inc. stock a top momentum play2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How ACADIA Pharmaceuticals Inc. stock performs after earningsRecession Risk & Long-Term Safe Investment Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Patterns & Reliable Volume Spike Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Real time alert setup for ACADIA Pharmaceuticals Inc. performanceIPO Watch & Long-Term Investment Growth Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsMarket Risk Summary & Weekly Momentum Stock Picks - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Why ACADIA Pharmaceuticals Inc. stock is rated strong buyWeekly Volume Report & High Yield Equity Trading Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic - Barchart.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Merger Talk: What catalysts could drive ACADIA Pharmaceuticals Inc. stock higherEntry Point & Fast Gaining Stock Strategy Reports - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Jobs Report & Growth Focused Investment Plans - newser.com

Oct 27, 2025

Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$36.67
price up icon 0.71%
$90.18
price down icon 1.60%
$28.95
price down icon 0.62%
$103.35
price down icon 1.60%
biotechnology ONC
$314.85
price down icon 0.63%
$166.95
price up icon 1.00%
Capitalizzazione:     |  Volume (24 ore):